References
- Walenga JM. An overview of the direct thrombin inhibitor argatroban. Pathophysiol Haemost Thromb. 2002; 32(Suppl 3)9–14
- Yeh RW, Jang IK. Argatroban: update. Am Heart J. 2006; 151: 1131–8
- White CM. Thrombin-directed inhibitors: Pharmacology and clinical use. Am Heart J. 2005; 149: S54–S60
- Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med. 2005; 353: 1028–40
- Gottdiener JS, Gay JA, VanVoorhees L, DiBianco R, Fletcher RD. Frequency and embolic potential of left ventricular thrombus in dilated cardiomyopathy: assessment by 2-dimensional echocardiography. Am J Cardiol. 1983; 52: 1281–5
- De Lorenzo F, Saba N, Kakkar VV. Blood coagulation in patients with chronic heart failure: evidence for hypercoagulable state and potential for pharmacological intervention. Drugs 2003; 63: 565–76
- Sharma ND, McCullough PA, Philbin EF, Weaver WD. Left ventricular thrombus and subsequent thromboembolism in patients with severe systolic dysfunction. Chest 2000; 117: 314–20
- Keren A, Goldberg S, Gottlieb S, Klein J, Schuger C, Medina A, et al. Natural history of left ventricular thrombi: their appearance and resolution in the posthospitalization period of acute myocardial infarction. J Am Coll Cardiol. 1990; 15: 790–800
- Nili M, Deviri E, Jortner R, Strasberg B, Levy MJ. Surgical removal of a mobile, pedunculated left ventricular thrombus: Report of 4 cases. Ann Thorac Surg. 1988; 46: 396–400
- Kuh JH, Seo Y. Transatrial resection of a left ventricular thrombus after acute myocarditis. Heart Vessels 2005; 20: 230–2
- Chu PH, Chen WJ, Lin PJ, Liao WB, Chiang CW, Lee YS. Thrombectomy for left ventricular protruding thrombi in a patient with dilated cardiomyopathy. Jpn Heart J. 1997; 38: 531–4
- Heik SC, Kupper W, Hamm C, Bleifeld W, Koschyk DH, Waters D, et al. Efficacy of high dose intravenous heparin for treatment of left ventricular thrombi with high embolic risk. J Am Coll Cardiol. 1994; 24: 1305–9
- Fareed J, Hoppensteadt D, Iqbal O, Tobu M, Lewis BE. Practical issues in the development of argatroban: a perspective. Pathophysiol Haemost Thromb. 2002; 32(Suppl 3)56–65
- Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000; 20: 318–29
- Swan SK, St Peter JV, Lambrecht LJ, Hursting MJ. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy 2000; 20: 756–70
- Hantgan RR, Jerome WG, Hursting MJ. No effect of clot age or thrombolysis on argatroban's inhibition of thrombin. Blood 1998; 92: 2064–74
- Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin. Thromb Haemost. 1994; 72: 381–6
- Berry CN, Girard D, Lochot S, Lecoffre C. Antithrombotic actions of argatroban in rat models of venous, ‘mixed’ and arterial thrombosis, and its effects on the tail transection bleeding time. Br J Pharmacol. 1994; 113: 1209–14